Virtu KCG Holdings LLC decreased its holdings in Blueprint Medicines Corporation (NASDAQ:BPMC) by 20.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,017 shares of the biotechnology company’s stock after selling 2,376 shares during the period. Virtu KCG Holdings LLC’s holdings in Blueprint Medicines Corporation were worth $457,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BPMC. UBS Asset Management Americas Inc. acquired a new position in shares of Blueprint Medicines Corporation in the 1st quarter valued at about $201,000. SG Americas Securities LLC grew its stake in shares of Blueprint Medicines Corporation by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 778 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Blueprint Medicines Corporation by 4,457.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,238 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 4,145 shares in the last quarter. Amalgamated Bank bought a new stake in shares of Blueprint Medicines Corporation in the 2nd quarter valued at approximately $232,000. Finally, Legal & General Group Plc grew its stake in shares of Blueprint Medicines Corporation by 31.8% in the 1st quarter. Legal & General Group Plc now owns 5,884 shares of the biotechnology company’s stock valued at $235,000 after buying an additional 1,419 shares in the last quarter. Institutional investors own 90.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/13/virtu-kcg-holdings-llc-reduces-stake-in-blueprint-medicines-corporation-bpmc.html.

Several brokerages recently commented on BPMC. Jefferies Group LLC reissued a “buy” rating and issued a $56.00 price target on shares of Blueprint Medicines Corporation in a research note on Tuesday, September 5th. BidaskClub raised Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Wedbush reissued an “outperform” rating and issued a $66.00 price target on shares of Blueprint Medicines Corporation in a research note on Tuesday, August 22nd. Zacks Investment Research cut Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Finally, BTIG Research began coverage on Blueprint Medicines Corporation in a research note on Friday, September 29th. They issued a “buy” rating and a $90.00 price target for the company. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. Blueprint Medicines Corporation has an average rating of “Buy” and a consensus target price of $63.47.

Shares of Blueprint Medicines Corporation (BPMC) opened at 64.62 on Friday. The company’s market cap is $2.53 billion. The company has a 50 day moving average price of $59.88 and a 200 day moving average price of $48.95. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $71.67.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.11). Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The firm had revenue of $5.89 million during the quarter, compared to analyst estimates of $5.96 million. During the same period in the prior year, the business posted ($0.70) EPS. The firm’s quarterly revenue was down 16.7% compared to the same quarter last year. On average, equities analysts expect that Blueprint Medicines Corporation will post ($3.66) earnings per share for the current year.

In other Blueprint Medicines Corporation news, CEO Jeffrey W. Albers sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $49.62, for a total transaction of $1,488,600.00. Following the transaction, the chief executive officer now owns 18,272 shares of the company’s stock, valued at approximately $906,656.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kate Haviland sold 5,449 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $66.44, for a total value of $362,031.56. The disclosure for this sale can be found here. In the last three months, insiders sold 69,305 shares of company stock worth $3,606,782. 3.40% of the stock is owned by insiders.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.